ADAGIO: a phase IIb international study of the Wee1 inhibitor adavosertib in women with recurrent or persistent uterine serous carcinoma.
Joyce F LiuAmit M OzaNicoletta ColomboAna OakninPublished in: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society (2021)
ClinicalTrials.gov: NCT04590248.
Keyphrases